Is Evexia Lifecare overvalued or undervalued?

As of 23 October 2025, Evexia Lifecare's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. However, based on the current financial metrics, the company remains overvalued. The PE ratio stands at an exceptionally high 212.41, while the EV to EBITDA ratio is also elevated at 206.57, suggesting that the market is pricing in significant growth expectations that may not be justified by the company's performance.
In comparison to its peers, Evexia Lifecare's ratios starkly contrast with those of Gulf Oil Lubricants and Veedol Corporation, which have PE ratios of 16.16 and 16.62, respectively, and EV to EBITDA ratios of 10.99 and 14.69. These peers are classified as very attractive, highlighting the disparity in valuation. Furthermore, Evexia's return metrics are concerning, with a year-to-date decline of 42.61%, significantly underperforming the Sensex's 8.21% gain during the same period. This underperformance reinforces the view that Evexia Lifecare is overvalued in the current market environment.